BCG

ImmunityBio Announces $320 Million Investment by Oberland Capital, with $210 Million Funded at Closing, Bringing Total Financing in 2023 to $850 Million

Retrieved on: 
Tuesday, January 2, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Immunotherapy, Food, Immune system, Jefferies Group, CIS, Bladder cancer, RIPA, FDA, PDUFA, Note, Biologics license application, BCG, Patient, Capital, VWAP, Patrick Soon-Shiong, Food and Drug Administration, Carcinoma in situ, NMIBC, BLA

ImmunityBio, Inc. ( NASDAQ: IBRX ), a clinical-stage immunotherapy company (“ImmunityBio” or the “Company”), today announced an up to $320 million royalty financing and equity investment in the Company by Oberland Capital, with $210 million of gross proceeds received at closing on December 29, 2023.

Key Points: 
  • ImmunityBio, Inc. ( NASDAQ: IBRX ), a clinical-stage immunotherapy company (“ImmunityBio” or the “Company”), today announced an up to $320 million royalty financing and equity investment in the Company by Oberland Capital, with $210 million of gross proceeds received at closing on December 29, 2023.
  • The proceeds will also be used to fund ongoing business operations and clinical trials expanding N-803 (Anktiva®) indications into multiple solid tumors.
  • Oberland Capital has also an option to purchase an additional $10 million of common stock at a future date.
  • Jefferies LLC acted as exclusive financial advisor to the Company on the transaction.

NEC Thailand collaborates with Industrial Estate Authority of Thailand to monitor and manage industrial waste in 14 industrial estates

Retrieved on: 
Friday, November 10, 2023
Carbon, Associate, Industrial park, Risk, Movement, File association, Lung compliance, Health, Industrial waste, Waste management, Legislation, NEC, BCG, Ministry, Safety, Data management, Information technology, Environment

Mr. Ichiro Kurihara, President, NEC Corporation (Thailand) Ltd., said, "NEC designed a comprehensive structure and system to support both public and private industrial sectors.

Key Points: 
  • Mr. Ichiro Kurihara, President, NEC Corporation (Thailand) Ltd., said, "NEC designed a comprehensive structure and system to support both public and private industrial sectors.
  • This system, utilizing cutting-edge technology and NEC's expertise in creating efficient and sustainable waste management systems, enables efficient management and tracking of industrial waste and by-products.
  • Associate Professor Dr. Veeris Ammarapala, Governor, Industrial Estate Authority of Thailand, revealed that the organization has been developing a real-time industrial waste tracking system since 2019.
  • Prof. Dr. Veeris added, "NEC's Real-Time Industrial Waste Tracking System that IEAT is using will further enhance the efficiency of waste tracking and reduce the rate of illegal waste disposal.

Ractigen Therapeutics Advances into Clinical Stage with Groundbreaking saRNA Drug, RAG-01

Retrieved on: 
Wednesday, December 6, 2023
RNA, Bladder cancer, Therapy, Clinical trial, Pharmacokinetics, BCG, SaRNA, RNAa, Patient, Safety, NMIBC, Pharmaceutical industry

JIANGSU, China, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Ractigen Therapeutics, a leader in the field of small activating RNA (saRNA) therapeutics, is excited to announce the submission of a clinical trial application in Australia.

Key Points: 
  • JIANGSU, China, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Ractigen Therapeutics, a leader in the field of small activating RNA (saRNA) therapeutics, is excited to announce the submission of a clinical trial application in Australia.
  • This milestone marks Ractigen's transition into clinical development, with RAG-01 targeting NMIBC.
  • RAG-01 is recognized as the second saRNA drug worldwide to enter clinical trials and the first of its kind in China to achieve this critical milestone.
  • This development signifies a remarkable advancement in RNA-based therapeutic applications, especially in the context of challenging cancer treatments.

Protara Therapeutics Announces Presentation of Additional Encouraging Data from Phase 1a ADVANCED-1 Trial of TARA-002 in NMIBC at the 24th Annual Meeting of the Society of Urologic Oncology

Retrieved on: 
Thursday, November 30, 2023
Chills, Fever, CIS, Carcinoma, Fatigue, Headache, Urinary bladder, Therapy, Cancer, Society, Urination, BCG, Neoplasm, System, SUO, Bacillus, Patient, NMIBC, Pharmaceutical industry

The data will be featured during a poster session at the 24th Annual Meeting of the Society of Urologic Oncology (SUO) being held in Washington, D.C. from November 28, 2023 through December 1, 2023.

Key Points: 
  • The data will be featured during a poster session at the 24th Annual Meeting of the Society of Urologic Oncology (SUO) being held in Washington, D.C. from November 28, 2023 through December 1, 2023.
  • The patient who did not achieve HGRFS was dosed at 10KE, the lowest dose of TARA-002 offered in the trial.
  • Additional details on the trial design will be featured in a Trial in Progress poster at the SUO meeting.
  • A copy of the SUO posters will be available in the Events and Presentations section of the Company’s website: https://ir.protaratx.com .

Ryan Ranked Among the Best Places to Work in Pennsylvania by the Best Companies Group for the 12th Consecutive Year

Retrieved on: 
Thursday, December 21, 2023
Professional Services, Other Professional Services, Small Business, Human Resources, Finance, Consulting, Accounting, HR, Partnership, BCG, Environment, Central Penn Business Journal, Management

Ryan , a leading global tax services and software provider, has been named as one of the 2023 Best Places to Work in Pennsylvania by the Best Companies Group (BCG), in partnership with Central Penn Business Journal and Lehigh Valley Business.

Key Points: 
  • Ryan , a leading global tax services and software provider, has been named as one of the 2023 Best Places to Work in Pennsylvania by the Best Companies Group (BCG), in partnership with Central Penn Business Journal and Lehigh Valley Business.
  • This marks the 12th consecutive year Ryan has been recognized among Pennsylvania’s top workplaces.
  • “The 2023 Best Places to Work in Pennsylvania winners put employees first.
  • We join the Best Companies Group in congratulating this year’s honorees.”

Jemincare Announces 6 Approvals of Clinical Trials for its Innovative Drugs

Retrieved on: 
Tuesday, December 26, 2023
Hyperphosphatemia, Quality of life, Immunotherapy, Immune system, Klebsiella pneumoniae, FDA, PD-1, Renal cell carcinoma, Research, Bladder cancer, TKI, Cancer, Clinical trial, Pseudomonas aeruginosa, Acinetobacter baumannii, Chronic kidney disease, Phosphorus, Kidney disease, NMPA, BCG, Proteinuria, Escherichia coli, Kidney, Edema, National Medical Products Administration, Patient, Drug resistance, CKD, Dialysis, Gram-negative bacteria, Pharmaceutical industry

On December 20, NMPA has approved a clinical trial for JMKX003801 to treat serious infection caused by Gram-negative bacteria.

Key Points: 
  • On December 20, NMPA has approved a clinical trial for JMKX003801 to treat serious infection caused by Gram-negative bacteria.
  • Drug resistance of antibiotics, especially carbapenem resistance, in Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii and Pseudomonas aeruginosa has risen year by year.
  • On December 12, NMPA has approved a clinical trial for JMKX003142 to treat renal edema.
  • On December 12, FDA has approved a clinical trial for JMKX000197 to treat BCG-unresponsive non-muscle-invasive bladder cancer, and earlier on October 19, NMPA has approved the clinical trial.

Sungrow Named One of Fortune Future 50 Companies

Retrieved on: 
Wednesday, December 20, 2023
Boston, COP28, Pinterest, Spotify, PV, Boston Consulting Group, Lululemon Athletica, BCG, Future, DocuSign, Growth, Investment, Index, Renewable energy

Fortune, in collaboration with the Boston Consulting Group (BCG) since 2017, compiles the Future 50 list. To identify the Future 50, the BCG Henderson Institute used a "vitality" index to determine the rankings. The index is based on a top-down, market-based assessment of a company's growth potential, and a bottom-up analysis of its capacity to deliver, based on financial and non-financial metrics -- such as long-term strategic orientation, technology and investments, people, and structure.

Key Points: 
  • 12 spot on the 2023 Fortune Future 50 list, an exclusive recognition of the long-term growth potential among over 1,700 of the world's largest public companies.
  • Sungrow ranked alongside other reputed companies like Spotify, Lululemon, DocuSign, and Pinterest.
  • Fortune, in collaboration with the Boston Consulting Group (BCG) since 2017, compiles the Future 50 list.
  • The 2023 Fortune Future 50 companies show that despite near-term economic and geopolitical turbulence, the dominant patterns of long-term growth potential remain relatively stable.

Sungrow Named One of Fortune Future 50 Companies

Retrieved on: 
Wednesday, December 20, 2023
Boston, COP28, Pinterest, Spotify, PV, Boston Consulting Group, Lululemon Athletica, BCG, Future, DocuSign, Growth, Investment, Index, Renewable energy

Fortune, in collaboration with the Boston Consulting Group (BCG) since 2017, compiles the Future 50 list. To identify the Future 50, the BCG Henderson Institute used a "vitality" index to determine the rankings. The index is based on a top-down, market-based assessment of a company's growth potential, and a bottom-up analysis of its capacity to deliver, based on financial and non-financial metrics -- such as long-term strategic orientation, technology and investments, people, and structure.

Key Points: 
  • 12 spot on the 2023 Fortune Future 50 list, an exclusive recognition of the long-term growth potential among over 1,700 of the world's largest public companies.
  • Sungrow ranked alongside other reputed companies like Spotify, Lululemon, DocuSign, and Pinterest.
  • Fortune, in collaboration with the Boston Consulting Group (BCG) since 2017, compiles the Future 50 list.
  • The 2023 Fortune Future 50 companies show that despite near-term economic and geopolitical turbulence, the dominant patterns of long-term growth potential remain relatively stable.

enGene Appoints Lota S. Zoth, CPA, as Member of the Board of Directors

Retrieved on: 
Tuesday, December 19, 2023
Orexigen Therapeutics, Inovio Pharmaceuticals, CPA, Audit committee, Ernst & Young, MedImmune, Therapy, Controller, BCG, Chairperson, PSINet, Patient, Circassia Group, Compensation, Spark Therapeutics, History, Senior, Management

Ms. Zoth is an experienced Board of Directors member, having served in various roles at other companies, including Board Chair, Lead Independent Director, and Audit Committee Chair, as well as on Compensation, Transaction, Finance and Special Strategic Committees.

Key Points: 
  • Ms. Zoth is an experienced Board of Directors member, having served in various roles at other companies, including Board Chair, Lead Independent Director, and Audit Committee Chair, as well as on Compensation, Transaction, Finance and Special Strategic Committees.
  • She is currently serving on the Boards of the publicly traded companies Lumos Pharma, Inovio Pharmaceuticals, and 89 Bio.
  • Her past Board experience includes Zymeworks, Spark Therapeutics, Aeras, Orexigen Therapeutics, Circassia Pharmaceuticals, Hyperion Therapeutics, and Ikaria.
  • "I am honored to join the Board of Directors and to serve as Audit Committee Chair to help build a successful future for enGene and patients in need."

Alera Group Retirement Plan Services Acquires Fraser Group

Retrieved on: 
Tuesday, December 12, 2023
Asset Management, Professional Services, Insurance, BCG, Principal, UCLA, Acquisition, Research, Cornell University, Small business, Frasers Group, Carnegie Mellon University, Retirement, Industrial design, Financial adviser

Alera Group, a top independent national insurance and financial services firm, announced today the acquisition of Fraser Group, a retirement plan consulting practice led by retirement industry leader George Fraser.

Key Points: 
  • Alera Group, a top independent national insurance and financial services firm, announced today the acquisition of Fraser Group, a retirement plan consulting practice led by retirement industry leader George Fraser.
  • Fraser and his Scottsdale, Arizona-based team will continue in their existing roles and combine operations with the retirement plan services division of Benefit Commerce Group, an Alera Group Company (BCG).
  • “George Fraser is one of the leading lights in the retirement plan industry, and we’re thrilled to welcome him and his team to Alera Group Retirement Plan Services,” said Christian Mango, Executive Vice President and National Practice Leader, Retirement Plan Services.
  • “We looked at various scenarios for growing our practice’s reach, and Alera Group Retirement Plan Services was clearly the best fit,” Fraser added.